Lakefront Biotherapeutics

As of June 30, 2026, Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR carries a market capitalization of 10.15B, placing it among publicly traded companies globally. Its enterprise value stands at -3.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR has 1.31B shares outstanding.

As of June 30, 2026, Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR trades at a trailing price-to-earnings ratio of 2.90. The price-to-sales ratio is 1.75, and the price-to-book ratio stands at 0.53.

As of June 30, 2026, Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR maintains a current ratio of 32.84, meaning it holds 32.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR posted a return on equity (ROE) of 20.20, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 16.64, measuring how efficiently the asset base is converted into earnings. The company generates approximately 11.36M in revenue per employee across its workforce of 515.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.19 indicates how many times Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR recorded an income tax benefit of -98.58M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 3.41B, leaving 3.52B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR generated 5.85B in revenue and converted that into 3.52B in net income, yielding earnings per share of 2.63. EBITDA reached 2.38B, while operating income came in at 3.60B.

As of June 30, 2026, Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR holds 13.23B in cash and equivalents against 37.57M in total debt, resulting in a net debt position of -802.85M. Total book value stands at 19.27B, with working capital of 13.22B providing operational flexibility.

Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR produced -1.34B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -27.20M in capital expenditures, free cash flow totaled -1.37B - equivalent to -1.04 per share.

Over the twelve months ended June 30, 2026, Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR posted a gross margin of 97.45, reflecting its pricing power and cost economics. The operating margin of 61.57 and net profit margin of 60.23 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -13.14: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.36, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR shareholders.

As of June 30, 2026, Lakefront Biotherapeutics ADR Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR has an Altman Z-Score of 14.10, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.